Vir ex­pands part­ner­ship with Gates Foun­da­tion, adding $50M for HIV and malar­ia an­ti­body re­search ini­tia­tive

Just two days af­ter the US bought 600,000 more dos­es of Vir and GSK’s Covid-19 an­ti­body sotro­vimab to guard against Omi­cron, Vir Biotech­nol­o­gy an­nounced a part­ner­ship ex­pan­sion with the Bill and Melin­da Gates Foun­da­tion for its T-cell vac­cine pro­gram.

The part­ner­ship had been in place for a few years with Vir’s T-cell vac­cine pro­gram tar­get­ing TB and HIV. The foun­da­tion is putting up $50 mil­lion — $10 mil­lion in the form of a grant and the rest in an eq­ui­ty in­vest­ment.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN